Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 97 Results

Title
Intervention Indication Therapeutic Area Year Actions
Sacubitril-valsartan for previously untreated chronic heart failure with reduced ejection fraction in children Sacubitril-valsartan Chronic heart failure Cardiovascular System 2022 View  |  Download
Semaglutide for treating overweight and obesity in adolescents ages 12 to 17 years old Semaglutide (Ozempic) Obesity Endocrine, nutritional and metabolic disorders 2022 View  |  Download
Talquetamab for previously treated relapsed or refractory multiple myeloma Talquetamab Multiple myeloma (MM) Haematological Cancer and Lymphomas 2022 View  |  Download
Teclistamab for previously treated relapsed or refractory multiple myeloma Teclistamab Multiple myeloma (MM) Haematological Cancer and Lymphomas 2022 View  |  Download
Teduglutide for short bowel syndrome in infants Teduglutide Short bowel syndrome Gastroenterology 2022 View  |  Download
Teplizumab for the delay of clinical type-1 diabetes in at-risk patients aged 8 years and over Teplizumab (PRV-031; MGA031) Type 1 diabetes Endocrine Nutritional and Metabolic Disorders 2022 View  |  Download
Tislelizumab for treating unresectable, previously untreated hepatocellular carcinoma Tislelizumab (BGB-A317; BGBA-317) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2022 View  |  Download
Tislelizumab in combination with Paclitaxel, Cisplatin, and Radiotherapy for Oesophageal cancer Cisplatin (Platinol) , Paclitaxel (Taxol; paclitaxel albumin) , Tislelizumab (BGB-A317; BGBA-317) Squamous cell carcinoma (SCC) Head and Neck Cancer 2022 View  |  Download
Tislelizumab with chemotherapy for previously untreated unresectable or metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma Chemotherapy , Tislelizumab (BGB-A317; BGBA-317) Gastric cancer , Gastro-oesophageal junction adenocarcinoma Gastrointestinal Cancer 2022 View  |  Download
Tislelizumab with chemotherapy for previously
untreated advanced oesophageal squamous cell
carcinoma
Tislelizumab (BGB-A317; BGBA-317) Oesophageal squamous cell carcinoma Gastrointestinal Cancer 2022 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications